Cascade Biotechnology INC | Complement Therapeutics; novel approach to CNS/PNS disease management using the innate complement system.
Amyotrophic Lateral Sclerosis (ALS)-Autoimmune
Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurodegenerative disease with no available therapy. Components of the innate immune system are activated in the spinal cord and central nervous system of ALS patients.
Studies in the SOD1G93A mouse show deposition of C1q and C3/C3b at the motor end-plate before neurological symptoms are apparent, suggesting that complement activation precedes neurodegeneration in this model.
Analyzing post-mortem tissue of ALS donors may lead to a better understanding of the complement system’s role and it’s activation at the motor end-plate in human ALS. (Bahia , Idrissi , Bosch , Ramaglia , Aronica , Baas Troost D (2016) Complement activation at the motor end-plates in amyotrophic lateral sclerosis. J Neuroinflammation. Apr 7;13(1):72. doi: 10.1186/s12974-016-0538-2).